medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2007, Number 4

<< Back Next >>

Acta Med 2007; 5 (4)

Endovascular treatment of the occlusive peripheral arterial disease (OPAD) in the infrainguinal area

Águila MR, Marquina RM

Language: Spanish
References: 43
Page: 197-208
PDF size: 788.09 Kb.


ABSTRACT

Nowadays endovascular teraphy is an excellent alternative for the peripheral arterial disease, specially in the infrainguinal vessels. There are new devices for the procedures including: cutting balloon, cryoplasty, the use of Silverhawk device in concentric plaques such as the use of laser for the vessels below the knee. This technology is a fact and is specially useful in those patients with a great surgical risk. The technical success of revascularization by endovascular therapy in claudicate patients in the femoropopliteal sector exceeds 95%, the morbi-mortality rates don’t exceed 3%. The goal of this article is to show the new methods and techniques which are useful to a Vascular Surgeon for resolution of the peripheral arterial disease.


REFERENCES

  1. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter–Society Consensus (TASC). J Vasc Surg 2000; 31(1 Pt 2): S1–296.

  2. Cheng SW, Ting AC, Ho P. Angioplasty and primary stenting of high–grade, long–segment superficial femoral artery disease: is it worthwhile? Ann Vasc Surg 2003; 17: 430-437.

  3. Surowiec SM, Davies MG, Eberly SW et al. Percutaneous angioplasty and stenting of the superficial femoral artery. J Vasc Surg 2005; 41: 269-278.

  4. Gray BH, Sullivan TM, Childs MB et al. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long–segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg 1997; 25: 74-83.

  5. Laird JR. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther 2006; 13(Suppl 2): II30-1140.

  6. Lyden SP, Shimshak TM. Contemporary endovascular treatment for disease of the superficial femoral and popliteal arteries: an integrated device–based strategy. J Endovasc Ther 2006; 13(Suppl 2): II41-1151.

  7. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941-944.

  8. Kandarpa K, Becker GJ, Hunink MG et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol 2001; 12: 683-695.

  9. Mewissen MW. Self–expanding nitinol stents in the femoropopliteal segment: technique and mid–term results. Tech Vasc Interv Radiol 2004; 7: 2-5.

  10. Schlager O, Dick P, Sabeti S et al. Long–segment SFA stenting–the dark sides: in–stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther 2005; 12: 676-684.

  11. Arena FJ. Arterial kink and damage in normal segments of the superficial femoral and popliteal arteries abutting nitinol stents–a common cause of late occlusion and restenosis? A single–center experience. J Invasive Cardiol 2005; 17: 482-486.

  12. Scheinert D, Scheinert S, Sax J et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45: 312-315.

  13. Rabin Y, Taylor MJ, Wolmark N. Thermal expansion measurements of frozen biological tissues at cryogenic temperatures. J Biomech Eng 1998; 120: 259-266.

  14. Isner JM, Kearney M, Bortman S et al. Apoptosis in human atherosclerosis and restenosis. Circulation 1995; 91: 2703-2711.

  15. Fava M, Loyola S, Polydorou A et al. Cryoplasty for femoropopliteal arterial disease: late angiographic results of initial human experience. J Vasc Interv Radiol 2004; 15: 1239-1243.

  16. Laird JR, Biamino G, McNamara T et al. Cryoplasty for the treatment of femoropopliteal arterial disease: extended follow–up results. J Endovasc Ther 2006; 13(Suppl 2): II52-1159.

  17. Allie D, Berens E, Ramaiah V et al. Plaque excision in the peripheral vasculature. Endovasc. Today 2004; (Suppl2): II 3-11.

  18. Shafique S, Nachreyner R et al. Recanalization of infrainguinal vessels: Silverhawk, laser, and the remote superficial femoral artery endarterectomy. Sem Vasc Surg 2007; 20: 29-36.

  19. Mewissen MW. Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech Vasc Interv Radiol 2004; 7: 2-5.

  20. Ascher E, Marks NA, Hingorani AP. Duplex guided balloon angioplasty and subintimal dissection of infrapopliteal arteries: early results with new approach to avoid radiation exposure and contrast material. J Vasc Surg 2005; 42: 1114-1121.

  21. Mossop P, Cincotta M, Whitbourn R. First case reports of controlled blunt microdissection for percutaneous transluminal angioplasty of chronic total occlusions in peripheral arteries. Catheter Cardiovasc Interv 2003; 59: 255-258.

  22. Yang YM, Mehran R, Dangas G et al: Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. Catheter Cardiovasc Interv 2004; 63: 462-468.

  23. Wissgott C, Scheinert D, Rademaker J, Werk M, Schedel H, Steinkamp HJ. Treatment of long superficial femoral artery occlusions with excimerlaser angioplasty: long-term results after 48 months. Acta Radiol 2004; 45: 23-29.

  24. Scheinert D, Laird JR Jr, Schroder M, Steinkamp H, Balzer JO, Biamino G. Excimer laser-assisted recanalization of long, chronic superficial femoral artery occlusions. J Endovasc Ther 2001; 8: 156-166.

  25. Steinkamp HJ, Wissgott C, Rademaker J et al: Short (1-10 cm) superficial femoral artery occlusions: results of treatment with excimer laser angioplasty. Cardiovasc Intervent Radiol 2002; 25: 388-396.

  26. Lagerquist et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 10-1009-1019.

  27. Mauri et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 10-1020-27.

  28. Gale TL et al. Role of stents, drug-eluting stents, and stent-grafts in treatment of infrainguinal arterial disease. Sem Vasc Surg 2007; 20,1: 37-41.

  29. Popma JJ. Long-term safety and efficacy of drug-eluting stents: Two-year results of the REAL (REgistro AngiopLastiche dell’Emilia Romagna) Multicenter Registry. American Heart Association. Circulation 2007; 115(25): 3181-3188.

  30. Becquemin J-P, Favre J-P, Marzelle J. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg 2003; 37: 487-494.

  31. Duda SH, Bosiers M, Lammer J et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005; 16: 331-338.

  32. Fischer M, Schwabe C, Schulte K-L. Value of the Hemobahn/Viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. J Endovasc Ther 2006; 13: 281-290.

  33. Regar E, Serruys P, Bode C et al. Angiographic findings of the multi-center randomized study with the sirolimus-eluting Bx velocity balloon-expandable stent (RAVEL): sirolimus-eluting stent inhibit restenosis irrespective of the vessel size. Circulation 2002; 106: 1949-1956.

  34. Holmes D, Leon M, Moses J et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634-640.

  35. Schampaert E, Cohen E, Schluter M et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004: 43: 1110-1115.

  36. Lemos P, Lee C, Degertekin M et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003; 41: 2093-2099.

  37. Grube E, Silber S, Hauptmann K et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42.

  38. Serruys P, Degertekin M, Tanabe K et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stent: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 2004; 109: 627-633.

  39. Tanabe K, Serruys P, Grube E et al. TAXUS III trial: in-stent re stenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559-564.

  40. Stone G, Ellis S, Cox D et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109: 1942-1947.

  41. Goy J, Stauffer J, Siegenthaler M et al. A prospective randomized comparison between paclitaxel and sirolimus stent in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005; 45: 308-311.

  42. Meredith I, Ormiston J, Whitbourn R et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. Eurointervention 2005; 1: 157-164.

  43. Tsuchida K, Piek J, Neumann FJ et al. One-year results of a durable polymer everolimus-eluting stents in de novo coronary narrowings (The SPIRIT FIRST Trial). Eurointervention 2006). in press.




2020     |     www.medigraphic.com